V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330013208 | 330002974 | 1.78 | 74.9 | Curative (C) | 2017-06-28 | 2017-12-25 | CISPLATIN + RT | N | null | 330000172 | CISPLATIN + RT |
| 330013209 | 330003048 | 1.88 | 74.2 | Palliative (P) | 2013-09-16 | 2013-09-16 | CYCLOPHOSPHAMIDE + ETOPOSIDE + THALIDOMIDE | null | null | 330000516 | NOT MATCHED |
| 330013210 | 330007662 | 1.77 | 69.2 | Curative (C) | 2015-04-08 | 2015-04-13 | Cisplatin + Radiotherapy | N | Y | 330000894 | CISPLATIN + RT |
| 330013211 | 330013009 | 1.76 | 98 | Curative (C) | 2016-04-28 | 2016-04-28 | NB 13 cis-RA (Isotretinoin) | N | N | 330005334 | NOT MATCHED |
| 330013212 | 330003619 | 1.7 | 77.8 | Neo-adjuvant (N) | 2016-08-22 | 2016-10-17 | Cisplatin | N | N | 330005388 | CISPLATIN |
| 330013213 | 330003632 | 1.63 | 48.3 | Adjuvant (A) | 2018-06-02 | 2018-06-14 | Mifamurtide weeks 1-12 | Y | N | 330005520 | MIFAMURTIDE |
| 330013214 | 330007964 | 1.81 | 96 | Palliative (P) | null | 2018-10-16 | OST Mifamurtide | null | null | 330005616 | MIFAMURTIDE |
| 330013215 | 330003663 | 1.79 | 54.7 | Palliative (P) | 2018-03-23 | 2018-03-30 | Trial Unspecified | null | null | 330005682 | TRIAL |
| 330013216 | 330003742 | 1.63 | 42 | Curative (C) | 2014-12-12 | 2014-12-19 | DOXORUBICIN | N | null | 330006058 | DOXORUBICIN |
| 330013217 | 330003751 | 0 | 59.3 | Palliative (P) | 2014-08-01 | 2014-11-23 | METHOTREXATE | 2 | N | 330006926 | METHOTREXATE |
| 330013218 | 330010377 | 0 | 53.3 | Curative (C) | 2015-10-10 | 2016-01-19 | Cisplatin 7 day | N | N | 330007479 | CISPLATIN |
| 330013219 | 330003870 | 1.78 | null | Palliative (P) | 2017-11-09 | 2017-11-09 | Trial Unspecified | 2 | N | 330007616 | TRIAL |
| 330013220 | 330003899 | null | 67.4 | Adjuvant (A) | 2016-02-29 | 2017-05-09 | MIFAMURTIDE | 02 | N | 330007724 | MIFAMURTIDE |
| 330013221 | 330003944 | null | null | Curative (C) | null | 2015-01-17 | Trial Unspecified | null | null | 330007971 | TRIAL |
| 330013222 | 330010436 | null | 64 | Palliative (P) | null | 2014-08-09 | DOXORUBICIN | N | null | 330008138 | DOXORUBICIN |
| 330013223 | 330004001 | 1.65 | 18 | Curative (C) | null | 2016-06-04 | DOXORUBICIN | null | null | 330008194 | DOXORUBICIN |
| 330013224 | 330004119 | null | 84 | Palliative (P) | 2017-08-28 | 2018-06-18 | CISPLATIN + FLUOROURACIL | N | N | 330008951 | CISPLATIN + FLUOROURACIL |
| 330013225 | 330004125 | 1.8 | 89 | Disease modification (D) | 2019-04-20 | 2019-04-20 | Rituximab | N | N | 330008977 | RITUXIMAB |
| 330013226 | 330004131 | 1.86 | 63.3 | Curative (C) | 2015-02-28 | 2015-03-04 | OST Euramos 1 Closed Trial - AP | 02 | N | 330009031 | MAP |
| 330013228 | 330004161 | 1.71 | 78 | Palliative (P) | 2017-07-31 | 2017-11-13 | Etoposide + Ifosfamide (3 days) | N | N | 330009184 | ETOPOSIDE + IFOSFAMIDE |
| 330013230 | 330008301 | 1.65 | 69 | Palliative (P) | 2019-05-04 | 2019-09-04 | Rituximab | N | N | 330009744 | RITUXIMAB |
| 330013231 | 330004213 | 1.63 | null | null | null | 2018-10-09 | Cisplatin + Docetaxel +Fluorouracil | Y | null | 330009753 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 330013232 | 330008337 | null | 78 | Not known (9) | 2018-11-07 | 2019-04-28 | Cisplatin + Docetaxel +Fluorouracil | Y | null | 330010902 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 330013233 | 330008352 | 0 | 77 | Curative (C) | 2015-06-15 | 2015-06-29 | CARBOPLATIN + ETOPOSIDE | N | N | 330011097 | CARBOPLATIN + ETOPOSIDE |
| 330013235 | 330011750 | null | 69.9 | Curative (C) | 2019-10-30 | 2019-12-13 | Carboplatin + Etoposide iv&po | N | Y | 330011603 | CARBOPLATIN + ETOPOSIDE |
| 330013236 | 330013044 | 1.81 | 98.4 | Curative (C) | 2017-12-08 | 2018-09-22 | Cyclophosphamide + Dex + Rituximab | N | N | 330012557 | CISPLATIN + ETOPOSIDE |
| 330013237 | 330004684 | 0 | 75.5 | Adjuvant (A) | 2018-12-19 | 2018-12-22 | TEMOZOLOMIDE | 2 | N | 330013060 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330013238 | 330004715 | 1.7 | null | Palliative (P) | 2016-06-03 | 2016-06-07 | VAC | Y | N | 330013156 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 330013239 | 330004783 | 1.74 | 111.9 | Adjuvant (A) | 2019-07-20 | 2019-12-21 | Cytarabine High Dose | N | N | 330013538 | CYTARABINE HIGH DOSE |
| 330013241 | 330004834 | 1.76 | 91.6 | Curative (C) | 2016-02-24 | 2016-03-02 | Irinotecan + Temozolomide | N | N | 330014044 | IRINOTECAN + TEMOZOLOMIDE |
| 330013242 | 330004855 | 1.47 | 72.1 | Palliative (P) | 2016-01-13 | 2017-08-29 | Trabectedin | N | N | 330014295 | TRABECTEDIN |
| 330013243 | 330010739 | null | 104.6 | Palliative (P) | 2015-02-15 | 2015-02-15 | GemCarbo Days 1+8 | N | N | 330015927 | GEMCARBO |
| 330013244 | 330005111 | 1.89 | 93 | Curative (C) | 2017-08-01 | 2019-04-02 | Liposomal Doxorubicin (Caelyx) | 02 | N | 330016923 | LIPOSOMAL DOXORUBICIN |
| 330013245 | 330005121 | 0 | 32 | null | null | 2014-09-09 | Etoposide oral | N | N | 330016972 | ETOPOSIDE |
| 330013246 | 330005125 | null | 62.35 | Curative (C) | 2018-05-23 | 2018-09-29 | EURO-EWING | N | null | 330017013 | EURO-EWING |
| 330013248 | 330005205 | 1.71 | 0 | Curative (C) | 2018-06-17 | 2018-08-26 | Vinblastine | 2 | N | 330017807 | VINBLASTINE |
| 330013249 | 330008842 | 1.77 | 74.6 | Palliative (P) | 2019-03-04 | 2019-03-04 | Cytarabine low (10to20mg/m2) IV/SC | 1 | N | 330017874 | IMATINIB |
| 330013251 | 330005379 | 1.67 | 68.4 | Disease modification (D) | 2015-03-09 | 2015-03-12 | Ifosfamide | 2 | N | 330019906 | DACTINOMYCIN + VINCRISTINE |
| 330013252 | 330011907 | 0 | 76 | Curative (C) | 2015-11-10 | 2016-01-22 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 330020236 | ADE |
| 330013253 | 330008968 | 1.8 | null | Palliative (P) | 2018-11-21 | 2018-11-28 | Cyclophosphamide High Dose | null | N | 330020433 | CAPECITABINE + LOMUSTINE |
| 330013254 | 330010891 | 1.61 | 65 | Curative (C) | 2014-11-23 | 2015-05-21 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | 330021093 | MITOTANE |
| 330013255 | 330010894 | 1.75 | 12.3 | Curative (C) | 2018-07-23 | 2018-08-07 | Cladribine (subcut) 5 days | N | null | 330021120 | DOXORUBICIN + HD MTX |
| 330013256 | 330009044 | 1.38 | 58 | Palliative (P) | 2016-02-27 | 2016-03-12 | MA (Cytarabine 3g/m2) | N | null | 330021428 | UKALL2014 |
| 330013257 | 330009054 | 1.6 | 61 | Curative (C) | 2014-06-11 | 2014-12-21 | Doxorubicin + Olaratumab | N | N | 330021602 | CARBOPLATIN + DOXORUBICIN |
| 330013258 | 330005598 | null | null | null | 2017-02-17 | 2017-02-22 | RUXOLITINIB | N | null | 330021653 | PAC-PLAT |
| 330013259 | 330005616 | 1.68 | 87.3 | null | 2014-10-28 | 2014-10-29 | Cisplatin + Docetaxel | 02 | N | 330021734 | GEMCITABINE + PACLITAXEL |
| 330013261 | 330005727 | 1.79 | 60 | Curative (C) | 2019-08-29 | 2019-09-10 | IVA | 02 | N | 330023279 | CAPECITABINE + CARBOPLATIN |
| 330013262 | 330005745 | 1.68 | 82 | Palliative (P) | 2019-09-28 | 2020-01-04 | UKALL XII Induction Phase 2 | 02 | N | 330023355 | UKALL2014 |
| 330013263 | 330005827 | 1.62 | 51.5 | Palliative (P) | null | 2018-03-08 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330024003 | CISPLATIN + PACLITAXEL |
| 330013265 | 330005912 | null | 75.7 | Curative (C) | 2015-06-01 | 2016-02-21 | UKALL14- Ph 1 Induction | 99 | null | 330024541 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |